rawfin.tv
Biotech Stock Gains 372% Before Sale, New Pick Rises 40%
MarketsstocksAI Generated

Biotech Stock Gains 372% Before Sale, New Pick Rises 40%

By rawfin.tv Markets Desk||1 min read|AI-assisted · Methodology

A clinical-stage biotech company, focused on precision therapies for rare diseases, saw its stock surge 372% before being sold. Concurrently, a new stock pick in the sector has reportedly gained 40% in 2026.

biotechstock-performancerare-diseasesprecision-therapieshealthcare

Related Articles

Adidas Surges 37% to Record Q3 Profit, Lifts Full-Year Targets

Adidas Surges 37% to Record Q3 Profit, Lifts Full-Year Targets

stocks
EQT to Acquire Cleanaway Waste for $6.5 Billion

EQT to Acquire Cleanaway Waste for $6.5 Billion

stocks
S&P 500 Breaches Key Support as AI Sell-Off Pressures Tech Sector

S&P 500 Breaches Key Support as AI Sell-Off Pressures Tech Sector

stocks
US Chip Stocks Plunge 16% in Longest Losing Streak Since 2008

US Chip Stocks Plunge 16% in Longest Losing Streak Since 2008

stocks